JCB and Azer Turk Bank launch JCB merchant acquiring operations across the Republic of Azerbaijan

TOKYO & BAKU, Sept 17, 2024 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan’s only international payment brand, and Azer Turk Bank OJSC, Azerbaijan state-owned bank with state participation in authorized capital, are delighted to announce the launch of JCB merchant…

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

SINGAPORE, Sept 17, 2024 - (ACN Newswire via SeaPRwire.com) - Cordlife Group Limited (“Cordlife” or the “Company” and together with its subsidiaries, the “Group”), which has been approved to resume cord blood banking activities in Singapore in a controlled manner, today unveiled its enhanced processing and storage facility, featuring strengthened operational…

Japan International Aerospace Exhibition 2024: Japan’s largest comprehensive aerospace industry exhibition

The largest exhibition in Japan for 663 companies/organizations!Exhibitor information is now available on the web!Pre-registration and admission ticket sales begin on September 3 (Tue.)October 16 (Wed.) to October 19 (Sat.), 2024,at the West Exhibition Hall, Tokyo Big Sight*Trade Days: October 16 (Wed.) to 18 (Fri.), Trade & Public Day: October…

LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

TOKYO and RAHWAY, N.J., Sept 17, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSDoutside of the United States and Canada) today announced results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating LENVIMA® (lenvatinib), the orally…

Akeso’s Ivonescimab Plus Chemotherapy Shows Promising Early Results in First-Line Triple-Negative Breast Cancer

HONG KONG, Sept. 16, 2024 — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary data, with only a 10-month median follow-up, showed that…